A first-in-human phase 1 study of BXQ-350, a first-in-class sphingolipid metabolism regulator, in patients with advanced/recurrent solid tumors or high-grade gliomas.
Olivier RixeJohn L VillanoRobert WesolowskiAnne M NoonanVinay K PuduvalliTrisha Michel Wise-DraperRichard CurryEmrullah YilmazCharlie CruzeBesim OgretmenGilles TapolskyRay TakigikuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
BXQ-350 was well tolerated as monotherapy at doses up to 2.4 mg/kg. It provided some lasting clinical benefit in patients with recurrent solid malignancies across several tumor types, consistent with a decreased systemic S1P/ceramide metabolic rheostat. BXQ-350 warrants further clinical investigation alone and combined with standard-of-care for advanced solid tumors.